Stockreport

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycysti...

Regulus Therapeutics Inc.  (RGLS) 
Last regulus therapeutics inc. earnings: 3/12 04:37 pm Check Earnings Report
US:NASDAQ Investor Relations: regulusrx.com/investors
PDF Patients receiving 300 mg farabursen demonstrated a mean halting of height-adjusted total kidney volume (htTKV) growth over 4 months Exploratory analysis of patients [Read more]